Global Primary Peritoneal Cancer Therapeutics Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|原發性腹膜癌症治療藥的全球市場:2020年∼2027年 Global Primary Peritoneal Cancer Therapeutics Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
The Global Primary Peritoneal Cancer Therapeutics Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Primary peritoneal cancer (PPC) is a rare type of cancer. It starts in the thin layer of tissue lining the inside of the abdomen. This tissue lining is called the peritoneum. PPC cells are the same as the most common type of ovarian cancer cells because the lining of the abdomen and the surface of the ovary come from the same tissue where embryos develop in the womb. Most cancers are caused by many different factors working together. A minimal number of PPCs may be linked to the inherited faulty genes BRCA 1 and BRCA 2. These are the same genes that increase the risk of ovarian cancer and breast cancer. PPC mainly affects women. It's very rare in men. Most people are diagnosed above the age of 60. American research suggests that around 10 out of 100 (around 10%) of all women with ovarian, fallopian and peritoneal serous cancers have PPC. The symptoms of PPC include a swollen tummy (abdomen), abdominal pain, constipation or diarrhea, feeling or being sick, feeling bloated, loss of appetite. The treatment for PPC is the same as for advanced epithelial ovarian cancer: surgery, chemotherapy, and radiotherapy. The market is expected to drive in the future due to the high prevalence rate of ovarian cancers, metastatic gastric, intestinal cancers.
The global Primary Peritoneal Cancer Therapeutics market growth is driven by the rising number of reported incidences of peritoneal cancer due to increased awareness, number of patients suffering from metastatic gastric, intestinal, and ovarian cancers is expected to increase the incidences of peritoneal cancer, which would lead to an increase in the demand for primary peritoneal cancer therapeutics and also the growing demand for a multidisciplinary treatment regime in closed care are likely to boost the growth of the primary peritoneal cancer therapeutics market.
Increasing incidenece of metastatic gastric, intestinal, and ovarian cancers is expected to increase the incidences of peritoneal cancer.
According to the National Cancer Institute NIH, in 2018, an estimated 235,081 women were living with ovarian cancer in the United States and in 2021, it is estimated that there will be 21,410 new cases of ovarian cancer. Out of the whole diagnosed population, 15-20% cases have led to peritoneal metastases. In 2021, it is estimated that 26,560 new cases of gastric cancer are diagnosed. Patients who have gastric cancer have a higher chance (30%) of developing peritoneal cancer at some point in their disease. It is sometimes left untreated, as it cannot be detected by radiological imaging. This can also be one of the main reasons for lower reported incidences of peritoneal cancer, and hence, it is considered a very rare form of cancer.
Major side effects of Surgery and Chemotherapy is likely to hinder the market growth.
Surgery is usually the primary step in treating PPC. Some complications and side effects are Nausea and vomiting, Infection, fever, Wound problem, Fullness due to fluid in the abdomen, Shortness of breath due to fluid around the lungs, Anemia, Swelling caused by lymphedema, usually in the legs or arms, Blood clots, Difficulty urinating or constipation.
Each patient responds to the chemo differently. Some patients may have very few side effects, while others experience several. They include loss of appetite, mouth sores, increased chance of infection, bleeding or bruising easily, hair loss. These are one of the major factors restricting the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on Treatment Type, the global Primary Peritoneal Cancer Therapeutics market is segmented into Surgery, Targeted therapy, Hormone therapy, Chemotherapy, Radiation therapy.
There are two treatment methods available for peritoneal cancer patients, including treatment with palliative intent and curative intent. The first option involves treating palliative intent to reduce the pain, surgical intervention to resolve bowel obstruction, and treatment with systemic chemotherapy. The second treatment method with curative intent involves multidisciplinary action on peritoneal cancer with systemic chemotherapy, hyperthermic intraperitoneal chemotherapy, and tumor removal surgery.
The targeted therapy segment, along with chemotherapy, is expected to boost the growth of the primary peritoneal cancer therapeutics market.
Chemotherapy cancer treatment uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. One type of regional chemotherapy used to treat peritoneal cancer is Intraperitoneal (IP) chemotherapy. In this, anticancer drugs like carboplatin, paclitaxel are directly carried into the peritoneal cavity (the space that contains the abdominal organs) through a thin tube, and Hyperthermic intraperitoneal chemotherapy (HIPEC) treatment is used during surgery that is being studied for advanced ovarian cancer. After the surgeon has removed as much tumor tissue as possible, warmed chemotherapy is sent directly into the peritoneal cavity.
Targeted therapy is another type of treatment that uses drugs or other substances to identify and attack specific cancer cells. For instance, Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) are targeted therapy drugs that block DNA repair and cause cancer cells to die. Drugs like Olaparib, rucaparib and niraparib are PARP inhibitors that may be used to treat peritoneal cancers. Olaparib and Rucaparib may also be used as maintenance therapy to treat Reoccurred ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
For instance, Elevar Therapeutics and Tanner Pharma Group Announced the Global Named Patient Program to Provide Access to Apealea® (micellular paclitaxel) on July 27, 2020.
Based on End-User, the global Primary Peritoneal Cancer Therapeutics market is segmented into Hospitals, Cancer Research centers, Surgical centers, others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.
North America served the largest share of the market due to the increasing prevalence of Peritoneal Cancer cases. According to the American Cancer Society, in 2021, it is estimated that there will be 21,410 new cases of ovarian cancer. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and targeted therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products. For instance, GSK undergoing Phase III clinical trials (NCT04679064) of GSK3985771 †niraparib Zejula- Advanced Ovarian cancer 1L maintenance combo with dostarlimab (Poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor).
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Takeda Pharmaceuticals conducted A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients with Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens.
The Global Primary Peritoneal Cancer Therapeutics Market is quite competitive with some key competitors like Eli Lilly and company, Amgen, GlaxoSmithKline Plc, Hoffmann-La Roche, Novartis Pharmaceuticals Corporation, Genentech USA, Astra Zeneca, Sanofi Aventis, Janssen Pharmaceuticals, Inc and Pfizer. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.
For instance, according to clinicaltrials.gov; Novartis Pharmaceuticals in Collaboration with GlaxoSmithKline- A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Hoffmann-La Roche Ltd
Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009.
Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.
Hoffmann-La Roche-An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab (Avastin) in the Front-Line Management of Advanced/Metastatic Primary Peritoneal Cancer in Real-life Clinical Practice.
The global Primary Peritoneal Cancer Therapeutics Market report would provide an access to an approx. 53 market data table, 45 figures and 240 pages.
LIST NOT EXHAUSTIVE